KELSEY MCCOY: Open Payments
NPI 1689043952 · LEBANON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$772 in 46 payments from 13 companies in 2025. Trend: 2023 $961 · 2024 $854 · 2025 $772
Food & beverage: $772
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $163 |
| Novo Nordisk Inc | 6 | $110 |
| Janssen Pharmaceuticals, Inc | 4 | $75 |
| AstraZeneca Pharmaceuticals LP | 4 | $71 |
| GlaxoSmithKline, LLC. | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Abbott Laboratories | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| PFIZER INC. | 2 | $35 |
| Neurocrine BioSciences, Inc. | 1 | $24 |
Products named: VRAYLAR, SPRAVATO, TRELEGY ELLIPTA, REXULTI, FREESTYLE LIBRE 3, Wegovy, FARXIGA, UBRELVY.
Industry payments across VA — which companies pay providers there.
